GLP-1
Tirzepatide
SaveA dual GLP-1/GIP receptor agonist (Mounjaro for diabetes, Zepbound for obesity) that demonstrated weight loss exceeding 20% in the SURMOUNT trials, surpassing GLP-1 monotherapy.
Quick verdict
Currently the most efficacious approved anti-obesity medication, with ~21% mean weight loss in SURMOUNT-1. Dual mechanism may offer advantages over pure GLP-1 RAs.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
SURMOUNT-1 showed 20.9% mean weight loss at the highest dose (15 mg) over 72 weeks. SURPASS trials demonstrated superior glycemic control versus semaglutide 1 mg. The GIP receptor component may enhance tolerability and provide additional metabolic effects beyond GLP-1 alone.
Benefits
- ~21% mean weight loss at highest dose in SURMOUNT-1
- Superior glycemic control versus semaglutide 1 mg
- Dual GLP-1/GIP mechanism with potentially better tolerability
- Once-weekly subcutaneous injection
Dosage notes
Titrate from 2.5 mg to 5, 10, or 15 mg SC weekly based on tolerability and response.
Side effects
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Injection site reactions
Who should be cautious
Contraindicated in personal or family history of medullary thyroid carcinoma or MEN2. GI side effects are the most common reason for discontinuation.
What this page cannot tell you
Long-term cardiovascular outcomes data (SURPASS-CVOT) is not yet reported. Weight regain after discontinuation is expected, as with other GLP-1 RAs.
Leaderboard scores
- Weight loss92
- Longevity50
Write a review
Sign in to write a review.